Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SEA-CD40 |
Synonyms | |
Therapy Description |
SEA-CD40 is a monoclonal antibody to TNFRSF5 (CD40), which mimics the binding of the ligand, CD40LG (CD40L), to stimulate proliferation of T-cells and enhance an anti-tumor response (Cancer Res 2015;75(15 Suppl), Abstract nr 2472). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SEA-CD40 | CD40 Antibody 13 | SEA-CD40 is a monoclonal antibody to TNFRSF5 (CD40), which mimics the binding of the ligand, CD40LG (CD40L), to stimulate proliferation of T-cells and enhance an anti-tumor response (Cancer Res 2015;75(15 Suppl), Abstract nr 2472). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02376699 | Phase I | Pembrolizumab + SEA-CD40 SEA-CD40 | Safety Study of SEA-CD40 in Cancer Patients | Active, not recruiting | USA | 0 |